Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of <i>M. tuberculosis</i>.

"we have made python code publicly available that enables anyone to reproduce most of the figures and tables in a web browser window [ ].; in addition one can reproduce nearly all the tables and figures along with the supplementary data in a browser window ( i e no installation required) using python code we have made publicly available [ ] 10 1183/13993003 00239-2022 supp1 please note: supplementary material is not edited by the editorial office and is uploaded as it has been supplied by the author. in addition one can reproduce nearly all the tables and figures along with the supplementary data in a browser window ( i e no installation required) using python code we have made publicly available [ ] 10 1183/13993003 00239-2022 supp1 please note: supplementary material is not edited by the editorial office and is uploaded as it has been supplied by the author."

"Conflict of interest: E. Robinson is employed by Public Health England and holds an honorary contract with Imperial College London. I.F. Laurenson is Director of the Scottish Mycobacteria Reference Laboratory. S. Niemann receives funding from German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation, Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG)tion EXC 2167. P. Supply is a consultant at Genoscreen. T.C. Rodwell is funded by the National Institutes of Health and Dept of Defense, and receives salary support from the non-profit organisation FIND. T.C. Rodwell is a co-founder, board member and shareholder of Verus Diagnostics Inc., a company that was founded with the intent of developing diagnostic assays. Verus Diagnostics was not involved in any way with data collection, analysis or publication of the results. T.C. Rodwell has not received any financial support from Verus Diagnostics. The University of California San Diego (UCSD) Conflict of Interest office has reviewed and approved T.C. Rodwell's role in Verus Diagnostics Inc. T.C. Rodwell is a co-inventor of a provisional patent for a TB diagnostic assay (provisional patent: 63/048.989). T.C. Rodwell is a co-inventor on a patent associated with the processing of TB sequencing data (European Patent Application 14840432.0 and USSN 14/912,918). T.C. Rodwell has agreed to “donate all present and future interest in and rights to royalties from this patent” to UCSD to ensure that he does not receive any financial benefits from this patent. S. Shah is working and holding employee stock ownership plans at HaystackAnalytics Pvt Ltd (Product: Using whole genome sequencing for drug-susceptibility testing for Mycobacterium tuberculosis). G.F. Gao is listed as an inventor on patent applications for RBD-dimer-based coronavirus vaccines. The patents for RBD-dimers as protein subunit vaccines for SARS-CoV-2 have been licensed to Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China."

"Support statement: This work was supported by a Wellcome Trust/Newton Fund-MRC Collaborative Award (200205/Z/15/Z) and the Bill & Melinda Gates Foundation Trust (OPP1133541). Oxford CRyPTIC Consortium members are funded/supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC); the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Dept of Health, and the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, a partnership between Public Health England and the University of Oxford; the views expressed are those of the authors and not necessarily those of the NIHR, Public Health England or the Dept of Health and Social Care. J. Millard is supported by the Wellcome Trust (203919/Z/16/Z). Z. Yanlin is supported by the National Science and Technology Major Project, China (2018ZX10103001). K.M. Malone is supported by EMBL's EIPOD3 programme funded by the European Union's Horizon 2020 research and innovation programme under Marie Skłodowska Curie Actions. T.C. Rodwell is funded in part by funding from Unitaid (2019-32-FIND MDR). R. Siqueira Oliveira is supported by FAPESP (17/16082-7). L. Ferrazoli received financial support from FAPESP (2012/51756-5). B. Zhu is supported by the National Natural Science Foundation of China (81991534) and the Beijing Municipal Science and Technology Commission (Z201100005520041). N.T. Thuong is supported by the Wellcome Trust International Intermediate Fellowship (206724/Z/17/Z). G. Thwaites is funded by the Wellcome Trust. R. Warren is supported by the South African Medical Research Council. J. Carter is supported by the Rhodes Trust and Stanford Medical Scientist Training Program (T32 GM007365). A. Lalvani is supported by the NIHR Health Protection Research Unit in Respiratory Infections at Imperial College London. S. Grandjean Lapierre is supported by the Fonds de Recherche en Santé du Québec. C. Nimmo is funded by the Wellcome Trust (203583/Z/16/Z). A. Van Rie is supported by Research Foundation Flanders (FWO) under grant number G0F8316N (FWO Odysseus). G. Meintjes was supported by the Wellcome Trust (098316, 214321/Z/18/Z and 203135/Z/16/Z), and the South African Research Chairs Initiative of the Dept of Science and Technology and National Research Foundation (NRF) of South Africa (64787). The funders had no role in the study design, data collection, data analysis, data interpretation or writing of this report. The opinions, findings and conclusions expressed in this manuscript reflect those of the authors alone. L. Grandjean was supported by the Wellcome Trust (201470/Z/16/Z), the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (1R01AI146338), the GOSH Charity (VC0921) and the GOSH/ICH BRC (www.nihr.ac.uk). A. Brankin is funded by the NDM Prize Studentship from the Oxford Medical Research Council Doctoral Training Partnership and the Nuffield Dept of Clinical Medicine. D.J. Wilson is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (101237/Z/13/B), and by the Robertson Foundation. A.S. Walker is an NIHR Senior Investigator. T.M. Walker is a Wellcome Trust Clinical Career Development Fellow (214560/Z/18/Z). A.S. Lachapelle is supported by the Rhodes Trust. R.J. Wilkinson receives funding from the Francis Crick Institute, which is supported by the Wellcome Trust (FC0010218), UKRI (FC0010218) and CRUK (FC0010218). T. Cohen has received grant funding and salary support from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), US Agency for International Development (USAID) and Bill & Melinda Gates Foundation. The computational aspects of this research were supported by the Wellcome Trust Core Award (203141/Z/16/Z) and the NIHR Oxford BRC. Parts of the work were funded by the German Center of Infection Research (DZIF). The Scottish Mycobacteria Reference Laboratory is funded through National Services Scotland. The Wadsworth Center contributions were supported in part by cooperative agreement number U60OE000103 funded by the CDC through the Association of Public Health Laboratories and NIH/NIAID grant AI-117312. Additional support for sequencing and analysis was contributed by the Wadsworth Center Applied Genomic Technologies Core Facility and the Wadsworth Center Bioinformatics Core. SYNLAB Holding Germany GmbH for its direct and indirect support of research activities in the Institute of Microbiology and Laboratory Medicine Gauting. N. Rakotosamimanana thanks the Programme National de Lutte contre la Tuberculose de Madagascar."